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Abstract
Background: Melanoma cells are usually characterized by a strong proliferative potential and efficient invasive
migration. Among the multiple molecular changes that are recorded during progression of this disease, aberrant
activation of receptor tyrosine kinases (RTK) is often observed. Activation of matrix metalloproteases goes along
with RTK activation and usually enhances RTK-driven migration. The purpose of this study was to examine RTK-
driven three-dimensional migration of melanocytes and the pro-tumorigenic role of matrix metalloproteases for
melanocytes and melanoma cells.
Results: Using experimental melanocyte dedifferentiation as a model for early melanomagenesis we show that an
activated EGF receptor variant potentiates migration through three-dimensional fibrillar collagen. EGFR stimulation
also resulted in a strong induction of matrix metalloproteases in a MAPK-dependent manner. However, neither
MAPK nor MMP activity were required for migration, as the cells migrated in an entirely amoeboid mode. Instead,
MMPs fulfilled a function in cell cycle regulation, as their inhibition resulted in strong growth inhibition of
melanocytes. The same effect was observed in the human melanoma cell line A375 after stimulation with FCS.
Using sh- and siRNA techniques, we could show that MMP13 is the protease responsible for this effect. Along with
decreased proliferation, knockdown of MMP13 strongly enhanced pigmentation of melanocytes.
Conclusions: Our data show for the first time that growth stimuli are mediated via MMP13 in melanocytes and
melanoma, suggesting an autocrine MMP13-driven loop. Given that MMP13-specific inhibitors are already
developed, these results support the evaluation of these inhibitors in the treatment of melanoma.
Background
Growth factors control the fate of many cell types in the
body and usually stimulate proliferation, survival and
motility in cells that express the adequate receptor on
their surface. Therefore, availability of growth factors
and growth factor receptors must be tightly regulated
on multiple levels to prevent aberrant growth. However,
many tumors have developed mechanisms that render
them independent of exogenous growth factors. One
mechanism is the development of autocrine loops. Mul-
tiple tumors including melanoma produce high amounts
of EGF, TGF-a, PDGF, or bFGF which accelerates
tumor growth and goes along with a reduced patient
survival [1-5]. Furthermore, mutations in growth factor
receptors can generate continuous growth signals, e.g. in
glioblastoma, breast, ovarian, prostate and lung squa-
mous cell carcinomas, where the truncated epidermal
growth factor receptor version vIII is expressed [6-8].
The oncogenic EGFR variant Xiphophorus melanoma
receptor kinase (Xmrk) is also permanently active due
to mutations that result in constitutive dimerization of
this receptor tyrosine kinase [9,10]. Xmrk is the cause
for highly aggressive melanoma in the Xiphophorus fish
tumor model. It constitutes a very efficient oncogene
that induces the steps necessary for melanoma forma-
tion in vivo in the fish model [11-13] and also in vitro
in mammalian melanocytes [14,15]. * Correspondence: svenja.meierjohann@biozentrum.uni-wuerzburg.de
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progression, induction of cell motility and survival in the
extracellular matrix are considered to be crucial prerequi-
sites for a tumor cell to become metastatic. When a mela-
nocyte succeeds to leave its natural epidermal
environment and invades the dermis it has to face a new
surrounding, consisting mainly of collagen. The lack of a
proper cell-matrix attachment leads to an anoikis-like
state and drives these cells into apoptosis [16,17]. Activa-
tion of growth factor receptors, however, can both protect
the cells from apoptosis and induce migration in a three-
dimensional collagen environment [17-19]. Most migrat-
ing cells express either membrane-bound or secreted
matrix metalloproteases (MMP s )a tt h ec e l lf r o n tt h a t
digest the matrix and open space for the forward pushing
cell body. MMPs are commonly upregulated after growth
factor stimulation [20]. Although the best studied targets
of these proteases are various matrix components, a grow-
ing body of evidence reveals the importance of MMP-
dependent cleavage of other extra- and intracellular sub-
strates that have various cellular effects [21-23].
Here, we take advantage of the well defined transform-
ing abilities of the oncogene xmrk and use it as model to
analyze the cancer-inducing functions of receptor tyro-
sine kinases (RTK). In order to concentrate on RTK-
driven effects alone without influences from secondary
tumor-derived effects we are using Xmrk-expressing mel-
anocytes (melan a) rather than melanoma cells. Activa-
tion of Xmrk leads to transformation of these cells and
induces key features of the neoplastic phenotype of
melanoma cells [14]. One of these key features is the
occurrence of dedifferentiation, which can be directly
visualized by decresed pigmentation and reduced tyrosine
levels after Xmrk activation [15]. Besides dedifferentia-
tion and unlimited proliferation, Xmrk has been pre-
viously reported to induce cellular migration of
melanocytes in a two-dimensional migration assay [24]
and mediate cell survival in three-dimensional collagen
lattices [17]. In this study, we investigated the three-
dimensional migration behaviour. We found that Xmrk
activation induced melanocyte migration in an amoeboid
manner which is entirely independent of MMP activity.
Instead, blocking MMPs with a broadband inhibitor mix
stalled cell proliferation. The protease responsible for the
proliferation effect was MMP13, as demonstrated by
RNA knockdown experiments. Importantly, MMP13 was
also found to be necessary for the proliferation of the
human melanoma cell line A375.
Results
EGF stimulation of melanocytes leads to MAPK- and
PI3K-independent migration on collagen
To monitor the effects of signalling of the oncogenic
RTK Xmrk we used HERmrk-transgenic melanocytes
("melan-a Hm”) that transgenically express a chimeric
protein consisting of an extracellular EGFR- and an
intracellular Xmrk domain. It is important to note that
these cells do not express endogenous EGFR [15]. The
chimeric receptor displays the same intracellular signal-
ling as Xmrk and in addition allows EGF induction
instead of permanent activation. To find out which
matrix components are suitable for migration of melan-
a Hm we first performed a modified Boyden chamber
assay on transwell inlays that were either left uncoated
or were precoated with vitronectin, fibronectin, or col-
l a g e nI .W eu s e d1 0 0n g / m lo fE G F ,w h i c hi st h ec o n -
centration that proved to be optimal for migration on
uncoated transwell inlays [24]. The results demonstrate
that only uncoated and collagen-coated membranes con-
stitute a good migration substrate for the cells (Figure
1A). However, significant EGF-induced migration on
collagen I was only noted with reduced amounts of EGF
as stimulus (1 ng/ml, Figure 1B).
For evaluating which downstream components are
important for collagen-mediated cell migration, we per-
formed migration experiments at 1 ng/ml EGF in the
absence or presence of the following small molecule
inhibitors: AG1478 (blocks kinase activity of EGFR and
orthologues including Xmrk and HERmrk), LY294002
(blocks PI3K), PP2 (blocks SRC family kinases) and
U0126 (blocks MEK). Inhibition of SRC kinases and
HERmrk itself led to a reduction in cell motility
(Figure 1C), which is in accordance with previous obser-
vations monitoring two-dimensional migration in
absence of collagen [24]. Single and combined inhibition
of PI3K and MAPK pathways, however, revealed that
both pathways are dispensable for 2D migration of
HERmrk melanocytes (Figure 1C). However, both inhi-
bitors efficiently blocked the respective pathways at the
applied concentration of 10 μM (Additional file 1, Fig-
ure S1A) The same observation was made when an
independent MAPK inhibitor, namely PD184352, was
combined with the PI3K inhibitor (Additional file 1,
Figure S1B and, as inhibitor control: Additional file 2,
Figure S2A, right lanes).
EGF stimulation induces several MMPs in a MAKP-
dependent manner
As interaction of cells with matrix components often
induces both the secretion of matrix proteases and the
secretion of extracellular matrix components, we
screened for the expression of both groups of genes in
response to EGF. EGF strongly upregulated the tran-
scripts of matrix metalloproteases MMP1a,- 1b,- 3,- 9
and -13, which are not or only slightly expressed in
absence of EGF. The other investigated proteases or the
matrix components collagen I, IV, laminin and fibronec-
tin were not induced (Table 1). Inhibiting either
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Page 2 of 15Figure 1 EGF induces melanocyte motility on collagen I and the expression of several matrix metalloproteases.A - D :H mc e l l sw e r e
serum-starved for 24 h and seeded onto the upper chamber of transwell migration inlays. The transwell migration assays were stopped after 12
h. Cells were stained with crystal violet and the number of transmigrated cells was counted. A: Hm cells were seeded onto uncoated transwell
migration inlays or inlays previously coated with vitronectin (Vn), fibronectin (Fn) or collagen I (Col I). Where indicated, EGF were applied to the
lower chamber. B: Transwell migration assay of Hm cells seeded onto collagen I-coated inlays. The indicated concentrations of EGF were applied
to the lower chamber. C-D: Transwell migration assay of Hm cells seeded onto collagen I-coated inlays and stimulated with 1 ng/ml EGF,
applied to the lower chamber. Cells were additionally treated with AG1478 (AG), LY294002 (LY), PP2, U0126 (U0) (C) or a combination of
LY294002 and U0126 (LY + U0) (D). **: p < 0.001 (Student’s t test, paired, two-tailed). E: Hm cells were serum-starved for 24 h and subsequently
left untreated or treated with 100 ng/ml EGF in presence or absence of AG1478 or U0126. After 8 h, cells were harvested and reverse
transcription-PCR (in case of Mmp1a and Mmp1b) or realtime-PCR analysis (in case of Mmp3, -9 and -13) were performed. Realtime-PCR data
were normalized to expression of actin. **: p < 0.001 (Student’s t test, paired, two-tailed). F: Zymographic analysis of the supernatant of starved
or EGF-treated Hm cells after two days of stimulation.
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Page 3 of 15HERmrk or MEK with two independent inhibitors for
each pathway totally abolished the induction of each of
t h eM M P s( F i g u r e s1 Ea n dA d d i t i o n a lf i l e2 ,F i g u r e
S2A-B). The fact that MMP induction depends on the
MAPK pathway, which itself is not involved in the EGF
induced migration (see above), indicates that MMPs are
not required for EGF-induced migration on two-dimen-
sional collagen substrate.
To confirm MMP activity, we performed a gelatin
zymography, which is suitable for detecting active
MMP2, MMP9 and MMP13. After EGF stimulation, the
bands characteristic for active MMP9 and MMP13 were
enhanced (Figure 1F). To find out whether induction of
these MMPs is a shared feature of HERmrk and human
EGFR, we also treated melan-a cells transgenic for
human EGFR (melan-a HER) with EGF in absence or
presence of EGFR- and MEK inhibitors and monitored
transcriptional induction of MMPs. We observed
enhanced expression of Mmp1a,- 1b,- 3,a n d- 13,b u tn o
induction of Mmp9. Again, EGFR- and MEK inhibition
were effective (Additional file 2, Figure S2C) and
prevented the expression of all Mmp’s (Additional file 2,
Figure S2D). The parental cell line melan-a did not
respond to EGF stimulation (Additional file 2, Figure S2E).
EGF-stimulated melanocytes migrate in an amoeboid,
MMP- and MAPK-independent manner in
three-dimensional collagen gels
To monitor if MMP-independent migration only occurs
if the melanocytes are migrating on a flat surface or
whether it also takes place in three-dimensionally
migrating cells, the melanocytes were analyzed by time-
lapse videomicroscopy in a 3D model. The migrative
behaviour of melanocytes can be best observed when
cells are kept under experimental conditions that reflect
the composition of the dermis. Therefore Hm cells were
embedded in a three-dimensional chamber filled with
fibrillar collagen and overlayed with EGF-containing
medium. Cells were then monitored for 48 h. Monitor-
ing at high resolution revealed that migrating cells
squeezed through the matrix and changed their shape to
a rounded or ellipsoid appearance, seemingly without
degrading the matrix. This is reminiscent of amoeboid
migration in melanoma and other tumor cells in three-
dimensional migration model systems (Figure 2A,
arrows and Additional file 3, Movie S1) [25,26].
The concept of EGF-induced amoeboid migration in
melanocytes was directly addressed using broad-spec-
trum MMP inhibition (Ilomastat and MMP9/13 inhibi-
tor I). Inhibition of MMPs had no effect on migration
speed (Figure 2B), in agreement with the amoeboid
migration which is a migration mode independent of
matrix destruction by metalloproteases.
We also tested the effect of inhibiting the receptor
itself and its downstream target responsible for Mmp
upregulation, the ERK1/2 pathway. HERmrk signalling
was abrogated using the EGFR inhibitor AG1478, while
ERK1/2 inhibition was accomplished using the MEK
inhibitor U0126. We first controlled the efficiency of
both inhibitors in collagen gels. RT-PCR of all regulated
Mmp genes demonstrated a successful inhibition of tar-
get gene induction by AG1478 and U0126 (Figure 2C).
As expected, inhibition of HERmrk resulted in strongly
reduced cell migration (Figure 2B). However, activation
of ERK1/2 seemed to be dispensable for migration, as
U0126 had no effect on cell speed (Figure 2B). This was
unexpected, as ERK1 and ERK2 do not only induce
Mmp’s, but reportedly play a role in cytoskeleton rear-
rangement, which is a prerequisite for motility of many
cell types [27].
MMP inhibition results in a proliferation block of EGF-
treated melanocytes
Besides their contribution to ECM remodelling and
invasive migration, other functions of MMPs include the
proteolytic release of matrix-bound growth factors or of
transmembrane proteins. This would result in auto- or
paracrine outside-in-signalling. Thus, we monitored
apoptosis and cell cycle progression of EGF-stimulated
Table 1 RNA expression of proteases and matrix
components in response to longterm HERmrk stimulation
gene ENSEMBL reference induction by HERmrk
Mmp1a ENSMUSG00000043089 +++
Mmp1b ENSMUSG00000041620 +++
Mmp3 ENSMUSG00000043613 +++
Mmp7 ENSMUSG00000018623 -
Mmp8 ENSMUSG00000005800 -
Mmp9 ENSMUSG00000017737 +
Mmp11 ENSMUSG00000000901 -
Mmp13 ENSMUSG00000050578 ++
Mmp14 ENSMUSG00000000957 -
Mmp15 ENSMUSG00000031790 -
Mmp16 ENSMUSG00000028226 -
Mmp24 ENSMUSG00000027612 -
Upa ENSMUSG00000021822 -
CatD ENSMUSG00000007891 -
CatL ENSMUSG00000021477 -
Col1 ENSMUSG00000001506 -
Col4 ENSMUSG00000031502 -
Lam ENSMUSG00000032796 -
Fn1 ENSMUSG00000026193 -
The highest induction of Mmp1a,- 1 b, -3, -9 and -13 was seen at 8 h after EGF
induction. The symbols given in the table refer to gene induction at this
timepoint. +: induction 2-20-fold; ++: induction 20-100-fold; +++: induction
>100-fold.
Upa: urokinase plasminogen activator; CatD: cathepsin D; CatL: cathepsin L;
Col1: collagen I; Col4: collagen IV, Lam: laminin; Fn1: fibronectin I.
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Page 4 of 15HERmrk transgenic melanocytes in the absence or the
presence of MMP inhibitors.T oe x a m i n eap o s s i b l e
effect on cell proliferation, we stimulated starved cells
with EGF in absence or presence of the MMP inhibitor
mix (containing MMP inhibitors Ilomastat and MMP-
inhibitor 9/13) and followed their proliferation for ten
days. The inhibitors reduced cell proliferation to one
third of the control (Figure 3A). When we compared
the effect of single MMP inhibitors with the MMP inhi-
bitor mix, only MMP inhibitor 9/13 proved to be effec-
tive in blocking proliferation (Figure 3B). Flow
cytometry analyses demonstrated that while EGF
Figure 2 EGF induces MMP-independent amoeboid migration in Hm cells. A: Hm cells were embedded in a three-dimensional collagen
matrix and overlaid with starving medium containing EGF. The pictures are a detail magnification of Additional file 3, Movie S1 and show the
migrative behaviour of a single cell that was photographed eight times consecutively with a time interval of 4 min between the pictures. The
arrow indicates areas of dense matrix where the cell has to contract its cell body. B: Analysis of the speed of Hm cells migrating in a three-
dimensional collagen gel. Cells were embedded into collagen in the presence of DMSO, AG1478, U0126 and a mixture of MMPI 9/13 and
GM6001 (Ilomastat). Where indicated, cells were overlaid with EGF-containing medium. Graphs display the speed of single cells that was
calculated from the time-lapse movies, and the mean speed for each condition is indicated. The following numbers of cells were examined: ctrl.,
EGF, EGF + U0126: n = 161 (for each); EGF + AG1478: n = 78; EGF + MMP inhibitors: n = 120. ***: p < 0.0001. C: Hm cells were embedded in
collagen matrix and stimulated with EGF as described above. The supernatant contained DMSO, AG1478 or U0126, respectively. After 8 h, where
maximal stimulation was seen before, whole collagen gels were used for RNA isolation and RT-PCR analysis of the indicated genes. In case of
Mmp1a and -1b a lower, unspecific DNA band was seen, which was presumably due to oligonucleotide multimers that can form in the absence
of specific template. The specific bands for MMP1a and -1b are indicated by an arrow.
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Page 5 of 15Figure 3 MMP inhibition results in strongly reduced proliferation of melan-a Hm cells. A: Hm cells were starved for two days in presence
of 1.5% dialyzed FCS and were then stimulated by the addition of 100 ng/ml EGF, either in absence or presence of the MMP inhibitor mix
containing MMP inhibitors MMPI 9/13 and Ilomastat. The number of cells per well after ten days of treatment is indicated. *: p < 0.05; **: p <
0.0001. B: Starved Hm cells were stimulated with EGF in absence or presence of Ilomastat, MMP9/13 inhibitor or a combination of both. Cell
proliferation was measured after 2, 4, 6, 8 and 10 days. C: Cells were starved as above and were incubated with EGF in absence or presence of
the MMP inhibitor 9/13. Their cell cycle state was monitored after 16, 20 and 24 h. The first accumulation of cells into S-phase is seen after 20 h.
The assay was performed three times, and a representative example is shown.
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Page 6 of 15treatment of starved HERmrk melanocytes resulted in
an increase of cells in S phase after 20-24 h, no cell
cycle progression was seen in presence of the MMP
inhibitor 9/13 (Figure 3C). In addition, a slight increase
of sub G1 cells seemed to occur in MMP inhibitor 9/13
treated cell populations, but this was not significant.
Western blot analysis of cleaved caspase 3, the effector
caspase downstream of intrinsic and extrinsic apoptosis
stimuli, showed no apoptosis induction (Additional file
4, Figure S3A). Thus, the prevailing effect of blocking
MMP9/MMP13 was the inhibition of cell cycle
progression.
Cell cycle progression of the human melanoma cell line
A375 is also blocked by MMP inhibition
To address whether MMP-dependent cell cycle progres-
sion is also a feature of human melanoma cells, we
tested the melanoma cell line A375. In contrast to
starved melan-a Hm cells, starved A375 cells already
expressed low amounts of MMP1,- 3,- 9,a n d- 13 (data
not shown). However, as we were interested in MMPs
that are induced in response to growth stimulatory sig-
nals, we also analyzed the expression of these four genes
in response to EGF and FCS. Under these conditions, an
induction was only measured for MMP13 (Figure 4).
Although EGFR stimulation of A375 results in pro-
tumorigenic cellular effects, such as enhanced survival
[28], it is not sufficient to drive the cells into cell cycle
(own observations). Thus, we performed the prolifera-
tion experiments using 10% FCS as stimulant.
The results mirrored the situation previously observed
in melan-a Hm cells. Proliferation was blocked by the
MMP inhibitor mix, and the only inhibitor responsible
for this effect was MMP 9/13 (Figures 5A and 5B). The
progression of starved A375 cells into S phase, which is
seen 20 and 24 h after FCS stimulation, was prevented
in presence of MMP9/13 (Figure 5C).
MMP13 mediates cell proliferation in melanocytes and
melanoma cells
Ilomastat efficiently inactivates MMP1, MMP2, MMP3,
MMP8, and MMP9, while the only described targets of
the MMP9/13 inhibitor are MMP9 and MMP13. There-
fore we concluded that the effect of the MMP9/13 inhi-
bitor is MMP13-specific. Supportingly, the application
of another inhibitor (CP 471474), targeting MMP1, -2,
3, 9, and -13, as well as an independent MMP13-specific
inhibitor (CL 82198) showed the same effect on the Hm
and A375 cells (Additional file 5, Figure S4).
To validate this, we transfected melan-a Hm cells with
a retroviral plasmid expressing Mmp13-specific shRNA,
which resulted in a reduction of Mmp13 expression on
RNA and protein level (Figure 6A, left and middle
panel). Melan-a Hm shMMP13 cells proliferated much
slower than cells expressing a control plasmid (Figure
6B). Interestingly, we also observed that Mmp13 down-
regulation went along with a strong increase in pigmen-
tation, as visible by a 100% increase in melanin content
(Figure 6C, left and middle panel). This was accompa-
nied by enhanced levels of tyrosinase RNA (Figure 6C,
right).
A similar approach was done with the human mela-
noma cell line A375. As several tested shRNA con-
structs did not efficiently knock down the gene, we used
commercial siRNA for this cell line, which reduced
MMP13 transcript levels to approx. 33% (Figure 6D,
left). Western blot analysis also confirmed a reduction
in the pro-and active forms of the protein, with 60 and
48 kDa, respectively (Figure 6D, right). Instead of the
previously conducted long-term proliferation assays, we
performed a BrdU incorporation assay as a measure of
DNA replication 72 h after transfection of the respective
siRNA (Figure 6E). Knockdown of MMP13 decreased
BrdU incorporation to 60%. We also observed an
increased fraction of siMMP13-transfected cells in the
Figure 4 Upregulation of human MMP13 in response to FCS. A375 cells were starved for two days in presence of 0.5% dialyzed FCS and
stimulated by the addition of 100 ng/ml EGF or 10% FCS. After 4 and 8 h, cells were harvested and monitored for the expression of MMP13 by
realtime PCR. Human ribosomal S14 was used as reference gene. *: p < 0.05 (Student’s t test, paired, two-tailed).
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Page 7 of 15Figure 5 MMP inhibition results in strongly reduced proliferation of A375 cells.A :A 3 7 5c e l l sw e r es t a r v e df o rt w od a y si np r e s e n c eo f
1.5% dialyzed FCS and stimulated by the addition of 10% FCS, either in absence or presence of the MMP inhibitor mix containing MMP
inhibitors MMPI 9/13 and Ilomastat. The number of cells per well after ten days of treatment is indicated. B: Starved A375 cells were stimulated
with FCS in absence or presence of Ilomastat, MMP9/13 inhibitor or a combination of both. Cell proliferation was measured after 2, 4, 6, 8 and
10 days. C: Cells were starved as above and were incubated with FCS in absence or presence of the MMP inhibitor 9/13. Their cell cycle state
was monitored after 16, 20 and 24 h. The first accumulation of cells into S-phase is seen after 20 h. The assay was performed three times, and a
representative example is shown.
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Page 8 of 15Figure 6 MMP13 knockdown in murine melanocytes and the human melanoma cell line A375 reduces proliferation. A, left: Realtime-PCR
of Mmp13 expression in melan-a Hm cells transgenic for a control pRetroSuper vector (ctrl.) compared to melan-a Hm cells expressing pRS-
shMmp13. A, right, top: Western blot displaying the decrease of the pro-form of MMP13 after knockdown in murine melan-a Hm cells. Note that
only the human, but not the murine active form is recognized by the antibody (also see D). A, right, bottom: Zymography of unconcentrated
supernatant, showing a decreased MMP13 band after knockdown. B: Starved melan a Hm pRS and Hm pRS-shMmp13 cells were stimulated with
EGF, and cell proliferation was measured after 2, 4, 6, 8 and 10 days. C, left: Appearance of cell pellets of EGF-stimulated Hm cells either
transfected with the control vector or the pRS-shMmp13 vector. C, middle panel: Quantification of melanin in EGF-stimulated Hm cells either
transfected with the control vector or the pRS-shMmp13 vector. C, right: Realtime PCR analysis of tyrosinase transcript levels in control Hm cells
and Hm cells expressing pRS-shMmp13. b-actin was used as reference gene. D, left: Realtime-PCR of MMP13 expression in A375 cells transfected
with siRNA against MMP13 or an siRNA control, 72 h after transfection. D, right: Western blot of MMP13, showing the full-length (60 kDa) and
the active (48 kDa) form of the protein in A375 cells treated with control or MMP13-specific siRNA. E: BrdU incorporation of A375 cells
transfected with control siRNA or MMP13-specific siRNA. The right bar shows the BrdU incorporation of A375 cells, treated with MMP13-specific
siRNA, but in presence of the 48 h-conditioned supernatant from control siRNA-transfected cells. BrdU incorporation of the control cells is used
as reference and is set as 100%. The assay was performed three times independently. *: p < 0.05 (Student’s t test, paired, two-tailed)
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Page 9 of 15G0/G1 phase of the cell cycle when compared to control
cells (Additional file 6, Figure S5). However, the effect
was weaker than the effect seen in presence of the
MMP 9/13 inhibitor displayed in figures 3C and 5C.
Possibly, this is due to the incomplete MMP13 knock-
down. It is also likely that the arrest is more enhanced
in starved cells that are confronted with growth stimulus
and MMP inhibitor at the same time. If MMP13 is
knocked down in the normal growing cell culture, it
may block cell cycle progression in general, irrespective
of the cell cycle phase. This kind of behaviour is remi-
niscent of the effect of growth factor withdrawal, which
can block the cell cycle in G1 and G2, and might point
to the possibility that MMP13 releases an unidentified
growth factor. To investigate whether the potential
MMP13-dependent growth-promoting factor is secreted,
we treated siMMP13-transfected A375 cells with condi-
tioned supernatant from control siRNA-transfected cells.
This could significantly restore BrdU incorporation to
80% of the control (Figure 6E), indicating the presence
of a soluble growth-promoting factor.
In summary, these data indicate that MMP13 plays an
important role in the growth factor-induced prolifera-
tion of melanocytes and melanoma cells as well as in
the dedifferentiation of melanocytes.
Discussion
In most melanomas, MMPs are aberrantly expressed. All
MMPs upregulated in Hm cells were previously
reported to be produced in melanoma, in particular
MMP1 and -9 [29]. The cause of MMP expression in
melanoma is largely unknown, but continuous ERK sig-
nalling, e.g. by autocrine FGF- or B-Raf
V600E- signalling
is responsible for their expression in some melanoma
cell lines [30,31].
The generally favoured function of MMPs in mela-
noma progression is the remodelling of the extracellular
matrix that enables both the transition of radial to verti-
cal growth phase and angiogenesis in more advanced
stages of the disease [30,32,33]. However, although
tumor cells commonly express ample amounts of
MMPs, MMP-independent migration was reported for
melanoma, fibrosarcoma and breast cancer cells
[25,26,34-36].
Consistent with the concept of MMP-independent
migration, our data show that the EGF-induced upregu-
lation of MMP13 in melanocytes supports cell cycle
progression instead of invasive migration.
MMP13, also called collagenase-3, is expressed in a
very restricted manner in the human body, but is often
upregulated under pathological conditions, such as can-
cer and arthritis [37]. Under physiological conditions, it
is mainly expressed in bone and cartilage, where it helps
to remodel the growing tissue. Consequently, MMP13-/-
mice show defects in growth plate cartilage and dis-
turbed ossification, which is at least partly the result
from interstitial collagen accumulation [38]. Hence, col-
lagens, such as collagen II and IV, are the best investi-
gated MMP13 targets [39,40]. However, the role of
MMP13 in mediating melanocyte and melanoma cell
proliferation as described in this manuscript is in line
with emerging non-classical MMP functions in outside-
in signalling and cell cycle control. The subsequent sig-
nal transduction events responsible for this process are
unclear so far, but matrix- or cell surface proteins,
either activated or made accessible by MMP13 depen-
dent cleavage, may be involved. Generally, MMPs can
release growth factors such as HB-EGF and TGF-a,b u t
also secreted factors or proteins that can regulate
growth factor availability, such as IGFBP1-, -3 and -5
and FGF receptor [41-47]. In squamous cell carcinoma,
MMPs generate autocrine loops that are able to stimu-
late several receptors of the EGFR family [48]. It is well
possible that a similar effect occurs MMP13-depen-
dently in Hm and A375 cells. For MMP13, a wide sub-
strate specificity was described, and several non-matrix
substrates are already known, such as TGF-b,C T G F ,
fibrinogen and ICAM-1 [37,40,49-51]. Furthermore,
MMP9 is a confirmed target of MMP13, and it is also
involved in the cleavage of numerous substrates, includ-
ing integrin precursors and LIF [52,53]. Whether these
or yet unknown targets are responsible for proliferation
in melanoma will be investigated in the future.
Interestingly, protein expression of MMP13 is absent
from nevi, but was noted in almost 50% of cutaneous
melanoma [54]. A functional role for stromal MMP13 in
melanoma development was recently described in a
MMP13-/- mouse model [55]. In these mice, B16F1
melanoma grafts displayed reduced tumor growth and
strongly decreased metastasis and angiogenesis com-
pared to wildtype mice. Together with our data, it
appears that tumor cell - or stroma-derived MMP13
plays a role in several processes of melanoma develop-
ment. This makes it a potentially attractive drug target.
Selective MMP13-specific protease inhibitors are already
developed [56,57] and are currently used in mouse mod-
els for arthritis [58]. In future studies, we will investigate
the effect of specific MMP13 inhibitors in animal mela-
noma models.
Conclusions
Our data demonstrate that MMP13 links growth-stimu-
latory signals such as EGF and FCS to cell cycle pro-
gression in melanocytes and melanoma cells and to
dedifferentiation in melanocytes. The data indicate that
the protease is important for migration-independent
processes of melanoma formation, possibly by releasing
a yet unidentified growth factor. As MMP13 also plays a
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are already developed, it might be considered as a target
for the treatment of MMP13-sensitive melanoma.
Methods
Cell Culture
A375 cells were maintained in DMEM, 10% FCS in the
presence of penicillin/streptomycin. Mouse melanocytes
transgenic for the chimeric receptor HERmrk (melan-a
Hm) or human EGFR (melan-a HER) were cultivated
in DMEM, 10% FCS in the presence of cholera toxin
(12 nM; Calbiochem), TPA (200 nM; Calbiochem) and
penicillin/streptomycin [15]. Melan-a cells are a non-
transformed cell line that are dependent on TPA for cell
growth and proliferation. The following inhibitors were
used and applied in the mentioned concentrations, unless
stated otherwise:: AG1478 (20 μM); EGFR inhibitor, (10
μM), U0126 (10 μM); LY294002 (10 μM); PP2 (20 μM),
MMPI 9/13 (10 μM), GM6001 - also called Ilomastat -
(10 μM) (all from Calbiochem, Merck), PD184352 (2
μM) (Axon Medchem), CL 82198 (75 μM), CP 471474
(100 μM) (both from Tocris Bioscience). Ilomastat is an
efficient inhibitor of MMP1, -2, -3, -8 and -9, CP 471474
inhibits MMP1, MMP2, MMP3, MMP9, and MMP13,
MMPI 9/13 blocks MMP9 and MMP13 and CL 82198
specifically targets MMP13. Starving of cells was per-
formed in DMEM medium containing no additives but
1.5% dialyzed FCS (Invitrogen), unless indicated other-
wise. EGF (Tebu-Bio) was used in the concentrations
indicated in the text and figure legends.
Knockdown methods
For cloning of the shMMP13 knockdown vector, the oli-
gonucleotides gatccccGAGCACTACTTGAAATCATtt-
caagagaATGATTTCAAGTAGTGCTCtttttggaaa and
agcttttccaaaaaGAGCACTACTTGAAATCATtctctt-
gaaATGATTTCAAGTAGTGCTCggg, containing
t h et a r g e ts e q u e n c eo fm u r i n eMmp13 [ENSMU
SG00000050578], were annealed and cloned into pRe-
troSuper previously digested with BglII and HindIII. The
resulting plasmid was retrovirally delivered into melan-a
Hm cells and selected by puromycin treatment to obtain
stable cellular expression. For human melanoma cells,
commercially available control siRNA and siRNA
against human MMP13 (Smart Pool On Target Plus,
Thermo Scientific, [ENSG00000137745]) were used.
siRNA was transfected using X-treme gene transfection
reagent (Roche), according to the manufacturer’s recom-
mendations. Downregulation was monitored by real-
time-PCR.
Cell proliferation assay
Cells were starved for three days in DMEM containing
1.5% dialyzed FCS (Invitrogen) and seeded at 3 × 10
4
cells per well of a 6-well plate. Hm cells were treated
with 100 ng/ml EGF, and A375 cells were treated with
1 0 %F C Si na b s e n c eo rp r e s e n c eo f1 0μMI l o m a s t a t ,
10 μM MMP9/13 inhibitor 1, or both. The controls
were treated with the corresponding amount of DMSO.
Cells were harvested by trypsinization after 2, 4, 6, 8,
and 10 days, pelleted, resolved in PBS and counted
under the microscope.
BrdU incorporation assay
72 h after siRNA treatment, cells were incubated with
10 μM BrdU for 24 h. The following day, BrdU incor-
poration was quantified using a colorimetric BrdU cell
proliferation ELISA, as recommended by the manufac-
turer (Roche).
RNA isolation, reverse transcription and realtime
PCR analysis
RNA isolation was performed using TrIR solution
(ABGene) according to the manufacturer’s instructions.
0.5-2 μg of whole RNA was reversely transcribed using
the RevertAidTM First Strand cDNA Synthesis Kit (Fer-
mentas). For the reverse transcription-PCR analyses of
Mmp1a/-b [ENSMUSG00000043089], [ENSMUSG0
0000041620] expression in Hm cells, PCR was stopped
after 30 PCR cycles and visualized on an agarose gel. b-
actin was shown as control. For realtime PCR analysis,
fluorescence-based quantitative realtime PCR was
performed using the iCycler (Bio-Rad) for quantification
of the following transcripts: murine Mmp3
[ENSMUSG00000043613], Mmp9 [ENSMUSG00000
017737], Mmp13 (see above), Tyr [ENSMUSG0000000
4651], all additional genes from table 1, and well as
human MMP13 (see above). b-actin [ENSMUSG0000
0029580] and ribosomal gene S14 [ENSG00000164587]
were used as reference genes for murine and human
genes, respectively. Relative expression levels were calcu-
lated applying REST software [59]. For all genes indi-
cated, realtime analysis was performed at least three
times independently from three different cDNA tem-
plates. The respective oligonucleotide sequences are
available on request.
Cell lysis and Western blot analysis
Cells were lysed in lysis buffer (20 mM HEPES (pH 7.8),
500 mM NaCl, 5 mM MgCl2, 5 mM KCl, 0.1% deoxy-
cholate, 0.5% Nonidet-P40, 10 μg/ml aprotinin, 10 μg/
ml leupeptin, 200 μMN a 3VO4,1m MP M S Fa n d
100 mM NaF). 50 μgo fp r o t e i nw a sr e s o l v e db yS D S /
PAGE and transferred to nitrocellulose according to
standard Western blotting protocols. Anti-b-actin (C-4)
and anti-ERK2 (C-14) antibodies were purchased from
Santa Cruz Biotechnology. Anti-P-ERK1/2 (Thr202/
Tyr204), anti-P-AKT (Ser473) and anti-cleaved caspase
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ing/NEB, and anti-MMP-13 antibody was purchased
from Abnova.
Melanin quantification
Melan-a Hm cells from EGF-treated cell culture were
trypsinized, and 5 × 10
5 cells were spun down in an
Eppendorf centrifuge. The supernatant was discarded
and the pellet was dissolved in 1 N NaOH. Melanin
concentration was determined by measurement of opti-
cal density at 475 nm and compared to a standard curve
obtained using synthetic melanin (Sigma). Pigment
determination was performed three times independently.
Zymographic analysis
FCS-free culture media of melan-a Hm cells, untreated
or pretreated with EGF for two days, were harvested,
adjusted according to the cell number and concentrated
using Amicon Ultracel 10 k columns unless indicated
otherwise. Samples were mixed with 2× loading buffer
(50 mM Tris-HCl [pH 6.8], 10% [vol/vol] glycerol, 1%
[wt/vol] SDS, 0.01% [wt/vol] bromophenol blue,) and
resolved on an SDS-polyacrylamide gel containing
0.12 mg/ml gelatin (porcine skin type A; Sigma). Gels
w e r es o a k e df o r1hi n2 . 5 %T r i t o nX - 1 0 0 ,t h e nw a s h e d
twice with collagenase buffer (50 mM Tris-HCl
[ p H7 . 6 ] ,0 . 2MN a C l ,5m MC a C l 2, 0.2% Brij 35), and
incubated at 37°C for 18 h. Gels were then washed with
distilled water and incubated in Coomassie brilliant blue
staining solution (40% methanol, 10% acetic acid/0.025%
Coomassie brilliant blue R-250) at room temperature for
2 h. Subsequently, gels were washed for 24 h in distilled
water and scanned.
Flow cytometry
Cells were starved for three days in 1.5% starving med-
ium before being stimulated with 100 ng/ml EGF
(Tebu-Bio) (Hm cells) or 10% FCS (A375). Cells were
harvested after 0, 16, 20 and 24 h of stimulation and
fixed in 70% ethanol. For flow cytometry analysis, DNA
was stained with 69 mM propidium iodide in 38 mM
sodium citrate and 100 mg/ml RNase A for 30 min at
37°C. Samples were analyzed in a Beckman Coulter
Cytomics FC 500.
Transwell migration assay
2,5 × 10
4 Hm cells were serum-starved in DMEM, 1%
dialyzed FCS for 24 h and applied to the upper chamber
of a transwell inlay (polycarbonate, 10 mm diameter, 8
μm pores, Nunc) in DMEM with 1% dialyzed FCS.
Where indicated, transwell inlays were pre-coated with
3 μg/ml vitronectin (Biosource), 10 μg/ml collagen I
(Upstate Biotechnology) or 10 μg/ml fibronectin (BD
Biosciences), yielding fibrillar layers. The indicated
concentrations of EGF were applied to the lower cham-
ber, and inhibitors were applied in the given concentra-
tion to the upper and lower chamber. After 12 h, the
transwell assay was stopped. The cells on the upper side
of the membrane were removed with a cell scraper,
before the membrane was fixed for 5 minutes in metha-
nol and stained for 20 minutes with 2% crystal violet
dissolved in 2% ethanol. The membranes were then
washed with PBS and the number of cells on the lower
side of the membrane was counted. The migration rate
was determined in absolute numbers. At all conditions,
the assay was performed at least three times
independently.
Collagen matrix migration assay and cell tracking
Cells were embedded within a 3D fibrillar collagen
matrix (final collagen concentration: 1.67 mg/ml) and
either overlaid with starving medium (DMEM contain-
ing 2.5% dialyzed serum (Invitrogen)) or starving med-
ium containing 500 nM EGF, which was the optimal
concentration for migration of Hm cells under these
conditions. For the inhibition experiments, MEK inhibi-
tor U0126, MMP inhibitors Ilomastat and MMP9/13
inhibitor I, alone or in combination, AG1478 or the
respective amount of DMSO were added to the matrix
and the starving medium. The collagen matrix compo-
nent in the chamber was approximately 2/3 of the total
volume, the medium supernatant was 1/3. The chamber
was hermetically sealed with paraffine, incubated at
37°C for 48 h and migration was monitored by time-
lapse videomicroscopy. Locomotor parameters were
obtained by computer-assisted cell tracking and recon-
struction of the xy coordinates of cell paths for a step
interval of 4 minutes. For each condition, three indepen-
dent samples were measured, and the speed was calcu-
lated for 40 randomly chosen cells per sample. The
viability of the cells was >95% and did not change in
presence of EGF or inhibitors.
List of Abbreviations used
bFGF: basic fibroblast growth factor; BrdU: bromodeox-
yuridine; Col I: collagen I; DMEM: Dulbecco’sm o d i f i e d
Eagle’sm e d i u m ;D M S O :d i m e t h y ls u l f o x i d e ;E G F :e p i -
dermal growth factor; EGFR: epidermal growth factor
receptor; FCS: fetal calf serum; Fn: fibronectin; HB-EGF:
heparin-binding epidermal growth factor; HERmrk (or
Hm): human EGF receptor-Xmrk chimeric protein;
IGFBP: insulin-like growth factor binding protein;
MAPK: mitogen-activated protein kinase; MEK: mito-
gen-activated protein kinase kinase; MMP: matrix metal-
loprotease; PBS: phosphate-buffered saline; PDGF:
platelet-derived growth factor; PI3K: phosphoinositide-
3-kinase; RTK: receptor tyrosine kinase; TGF-a (or -b):
tumor growth factor a (or -b)); TPA: 12-O-
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Page 12 of 15tetradecanoyl-phorbol-13-acetate; Tyr: tyrosinase; Vn:
vitronectin; WCL: whole cell lysate; Xmrk: Xiphophorus
melanoma receptor kinase.
Additional material
Additional file 1: Figure S1 - Inhibition of MEK and PI3K in EGF-
treated melan-a Hm cells. A: Starved Hm cells were pretreated for 1 h
with the indicated concentrations of U0126 or LY294002 before 100 ng/
ml EGF was added for 10 minutes. Cells were lysed, and 50 μg was then
subjected to Western blot analysis and probed with the indicated
antibodies. ERK2 was used as control. B: Transwell migration assay of Hm
cells seeded onto collagen I-coated inlays and stimulated with 1 ng/ml
EGF, applied to the lower chamber. Cells were additionally treated with
10 μM LY294002 (LY), 2 μM PD184352 (PD) or a combination of
LY294002 and PD184352 (LY + PD) (D). **: p < 0.001 (Student’s t test,
paired, two-tailed).
Additional file 2: Figure S2 - MAPK-dependent MMP expression in
melan-a Hm and melan-a HER cells. A: Starved Hm cells were
pretreated for 1 h with 20 μM AG1478, 10 μM EGFR-I (both inhibitors
targeting EGFR and HERmrk), 10 μM U0126 or 2 μM PD184352 (both
MEK inhibitors) before 100 ng/ml EGF was added for 10 minutes. Cells
were lysed, and 50 μg was then subjected to Western blot analysis and
probed with the indicated antibodies. ERK2 was used as control. B: Hm
cells were serum-starved for 24 h and subsequently left untreated or
treated with 100 ng/ml EGF in presence or absence of 10 μM EGFR-I or 2
μM PD184352. After 8 h, cells were harvested and reverse transcription-
PCR was performed for the indicated genes (35 cycles). C: as in A, but
performed with melan-a HER cells. D: as in B, but performed with melan-
a HER cells, and with additional treatment with the inhibitors AG1478 (20
μM) and U0126 (10 μM). E: The starved parental cell line melan-a was
treated with EGF, and a reverse transcription PCR was performed for the
indicated genes (35 cycles). Pc = positive control (EGF-treated Hm cells);
nc = negative control (H2O).
Additional file 3: Movie S1 - Time-lapse movie of EGF-treated
melan-a Hm cells. Cells were visualized with an inverted microscope at
200-fold magnification and were photographed every 4 min for a total
of 48 h.
Additional file 4: Figure S3 - Inhibition of MMP9 and MMP13 does
not affect apoptosis in Hm and A375 cells. A: Starved Hm cells were
left untreated or were treated with 100 ng/ml EGF in the absence or
presence of the MMP9/13 inhibitor for 24 and 48 h. Cells were then
lysed and 50 μg of cell lysate was analyzed by Western blot. Apoptosis
induction was investigated using an antibody against cleaved caspase 3.
As apoptosis control, UV-irradiated A375 cells were used. ERK2 was used
as loading control. B: as in A, but performed with A375 cells and 10%
FCS as growth stimulus.
Additional file 5: Figure S4 - Inhibition of cell cycle progression by
two additional MMP inhibitors. A: Starved Hm cells were treated with
EGF in the absence or presence of the general MMP inhibitor CP 471474
(100 μM) or the MMP13-selective inhibitor CL 82198 (75 μM) and
incubated for 24 h. Their cell cycle state was analyzed by flow cytometry.
B: as in A, but performed with A375 cells and FCS as growth stimulus.
Additional file 6: Figure S5 - Knockdown of MMP13 delays cell cycle
progression in A375 cells. A375 cells were transfected with control- or
MMP13-specific siRNA for 72 h, and the cell cycle state was monitored by
flow cytometry. Starved A375 cells served as control.
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